Prostate cancer genetic testing: NCCN familial high-risk assessment: breast/ovarian.

The National Comprehensive Cancer Network (NCCN) clinical practice guidelines have become the most recognized standard for clinical policy in cancer care. The Genetic Breast and Ovarian Guideline was introduced in 1999 with an emphasis on BRCA1/2. Based on evidence linking prostate cancer to the BRCA genes, prostate cancer was added to the guideline as a criterion for risk assessment in 2013. The current criteria include aggressive/metastatic disease and family history of BRCA-related cancers.